A Retrospective Test-Negative Case-Control Study to Evaluate Influenza Vaccine Effectiveness in Preventing Hospitalizations in Children.
adolescent
immunization
influenza vaccine effectiveness
pediatric
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
16 11 2021
16 11 2021
Historique:
pubmed:
20
8
2021
medline:
23
11
2021
entrez:
19
8
2021
Statut:
ppublish
Résumé
Vaccination is the primary strategy to reduce influenza burden. Influenza vaccine effectiveness (VE) can vary annually depending on circulating strains. We used a test-negative case-control study design to estimate influenza VE against laboratory-confirmed influenza-related hospitalizations among children (aged 6 months-17 years) across 5 influenza seasons in Atlanta, Georgia, from 2012-2013 to 2016-2017. Influenza-positive cases were randomly matched to test-negative controls based on age and influenza season in a 1:1 ratio. We used logistic regression models to compare odds ratios (ORs) of vaccination in cases to controls. We calculated VE as [100% × (1 - adjusted OR)] and computed 95% confidence intervals (CIs) around the estimates. We identified 14 596 hospitalizations of children who were tested for influenza using the multiplex respiratory molecular panel; influenza infection was detected in 1017 (7.0%). After exclusions, we included 512 influenza-positive cases and 512 influenza-negative controls. The median age was 5.9 years (interquartile range, 2.7-10.3), 497 (48.5%) were female, 567 (55.4%) were non-Hispanic Black, and 654 (63.9%) children were unvaccinated. Influenza A accounted for 370 (72.3%) of 512 cases and predominated during all 5 seasons. The adjusted VE against influenza-related hospitalizations during 2012-2013 to 2016-2017 was 51.3% (95% CI, 34.8% to 63.6%) and varied by season. Influenza VE was 54.7% (95% CI, 37.4% to 67.3%) for influenza A and 37.1% (95% CI, 2.3% to 59.5%) for influenza B. Influenza vaccination decreased the risk of influenza-related pediatric hospitalizations by >50% across 5 influenza seasons.
Sections du résumé
BACKGROUND
Vaccination is the primary strategy to reduce influenza burden. Influenza vaccine effectiveness (VE) can vary annually depending on circulating strains.
METHODS
We used a test-negative case-control study design to estimate influenza VE against laboratory-confirmed influenza-related hospitalizations among children (aged 6 months-17 years) across 5 influenza seasons in Atlanta, Georgia, from 2012-2013 to 2016-2017. Influenza-positive cases were randomly matched to test-negative controls based on age and influenza season in a 1:1 ratio. We used logistic regression models to compare odds ratios (ORs) of vaccination in cases to controls. We calculated VE as [100% × (1 - adjusted OR)] and computed 95% confidence intervals (CIs) around the estimates.
RESULTS
We identified 14 596 hospitalizations of children who were tested for influenza using the multiplex respiratory molecular panel; influenza infection was detected in 1017 (7.0%). After exclusions, we included 512 influenza-positive cases and 512 influenza-negative controls. The median age was 5.9 years (interquartile range, 2.7-10.3), 497 (48.5%) were female, 567 (55.4%) were non-Hispanic Black, and 654 (63.9%) children were unvaccinated. Influenza A accounted for 370 (72.3%) of 512 cases and predominated during all 5 seasons. The adjusted VE against influenza-related hospitalizations during 2012-2013 to 2016-2017 was 51.3% (95% CI, 34.8% to 63.6%) and varied by season. Influenza VE was 54.7% (95% CI, 37.4% to 67.3%) for influenza A and 37.1% (95% CI, 2.3% to 59.5%) for influenza B.
CONCLUSIONS
Influenza vaccination decreased the risk of influenza-related pediatric hospitalizations by >50% across 5 influenza seasons.
Identifiants
pubmed: 34410341
pii: 6354891
doi: 10.1093/cid/ciab709
pmc: PMC8599178
doi:
Substances chimiques
Influenza Vaccines
0
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1759-1767Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : Division of Microbiology and Infectious Diseases
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Références
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Open Forum Infect Dis. 2017 Jul 24;4(3):ofx111
pubmed: 28852675
Euro Surveill. 2013 Jan 31;18(5):
pubmed: 23399423
Vaccine. 2015 Jan 1;33(1):246-51
pubmed: 24962752
Clin Infect Dis. 2017 Oct 15;65(8):1289-1297
pubmed: 28525597
Expert Rev Vaccines. 2017 Jul;16(7):1-14
pubmed: 28562111
Clin Infect Dis. 2019 Nov 13;69(11):1896-1902
pubmed: 30753349
Pediatrics. 2020 Nov;146(5):
pubmed: 33020249
Influenza Other Respir Viruses. 2013 Sep;7(5):729-37
pubmed: 23078073
Clin Infect Dis. 2019 May 2;68(10):1623-1630
pubmed: 30204855
Vaccine. 2016 Jan 2;34(1):77-82
pubmed: 26589519
JAMA Pediatr. 2020 Jul 1;174(7):705-713
pubmed: 32364599
J Infect Dis. 2019 Sep 13;220(8):1265-1275
pubmed: 30561689
Vaccines (Basel). 2018 May 21;6(2):
pubmed: 29883414
Vaccine. 2018 Apr 12;36(16):2166-2175
pubmed: 29548608
JAMA Netw Open. 2018 Oct 5;1(6):e183742
pubmed: 30646262
Pediatrics. 2016 Feb;137(2):e20153279
pubmed: 26738884
Euro Surveill. 2013 Jan 31;18(5):
pubmed: 23399424
JAMA. 2015 Oct 13;314(14):1488-97
pubmed: 26436611
MMWR Recomm Rep. 2019 Aug 23;68(3):1-21
pubmed: 31441906
J Infect Dis. 2017 Apr 1;215(7):1059-1099
pubmed: 28180277
J Infect Dis. 2016 Oct 15;214(8):1142-9
pubmed: 27095420
Pediatrics. 2011 Dec;128(6):e1474-81
pubmed: 22084328
Front Public Health. 2018 Mar 02;6:57
pubmed: 29552553
J Infect Dis. 2015 May 15;211(10):1529-40
pubmed: 25406334
JAMA. 2004 Sep 15;292(11):1333-40
pubmed: 15367555
PLoS One. 2014 Mar 25;9(3):e92153
pubmed: 24667168
Clin Infect Dis. 2020 May 6;70(10):2121-2130
pubmed: 31298691
Clin Infect Dis. 2019 Nov 27;69(12):2153-2161
pubmed: 30753347
J Pediatric Infect Dis Soc. 2019 Dec 27;8(6):539-549
pubmed: 30358877
Pediatrics. 2017 May;139(5):
pubmed: 28557757
Clin Infect Dis. 2016 Dec 29;64(5):544-550
pubmed: 28039340